30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: Smith & Nephew

$696MM, +3% (Established Markets flat, Emerging/International +24%)

  • Hips $150MM, +3% (excluding metal-on-metal, +4%; U.S. -3%, ex-U.S. +3%)
  • Knees $196MM, +2% (U.S. +2%, ex-U.S. +3%)
  • Sports Medicine Joint Repair $118MM, +7%
  • Arthroscopic Enabling Technologies $101MM, -1%
  • Trauma $115MM, +2%


  • Still feeling impact from high exposure to Europe, position in product cycle, metal-on-metal
  • Like-for-like pricing pressure negative and consistent with recent quarters
  • German orthopaedic market -13% in quarter
  • Hip growth led by REDAPT, ANTHOLOGY and R3
  • JOURNEY II BCS Knee gaining momentum; running more training and putting more instrument sets into field
  • 20% of knee business now using VISIONAIRE patient matching technology
  • U.S. Direct-to-consumer campaign supporting good performance in core knees featuring VERILAST surface
  • Expanding HEALICOIL REGENESORB biocomposite suture anchor range
  • >80 U.S. trauma reps in place
  • In 4Q, completed acquisitions of distributor in Turkey and Adler Mediequip/Sushrut Surgicals in India
  • In 4Q, hosting education that combines arthroplasty and arthroscopy
  • 4Q product launches include HA POLARSTEM for hips (U.S.), R3 smaller ceramic liners, HEALICOIL, LED light source, TRIGEN INTERTAN nail range
  • 1H14 product launches include JOURNEY II range, expanding hip anchors, SURESHOT upgrades, expanded upper extremities portfolio and trauma plates/nails